Sebastian Schneeweiss, ScD, MD, FISPE

Professor of Medicine
BWH Div of Pharmacoepidemiology and Pharmacoeconomics
Boston, Massachusetts, United States

Sebastian Schneeweiss, MD, ScD, is a Professor of Medicine and Epidemiology at Harvard Medical School and Chief of the Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women’s Hospital.
His research focuses on the comparative effectiveness and safety of biopharmaceuticals. He has developed analytic methods to improve the scientific validity of epidemiologic analyses using complex longitudinal healthcare databases for newly marketed medical products. The overarching theme of his research is applying advanced real-world data analytics for regulatory decision making transparently and in rapid cycles. His work is published in >400 articles. His work is funded by NIH, PCORI, Arnold Foundation, IMI, and FDA where he is also a voting consultant.
Dr. Schneeweiss is Principal Investigator of the FDA Sentinel Innovation Center funded by FDA/CDER and Methods Lead of the FDA Sentinel program. He is Past President of the International Society for Pharmacoepidemiology and is Fellow of the American College of Epidemiology, the American College of Clinical Pharmacology, and the International Society for Pharmacoepidemiology.
He received his medical training at the University of Munich Medical School and his doctoral degree in pharmacoepidemiology from Harvard.

Aetion Inc. (Consultant/Advisory Board)Boehringer Ingelheim (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)

Presentation(s):

• Applied Sensitivity Analyses in Pharmacoepidemiology Database Studies

  Thursday, August 25, 2022
  2:00 PM – 6:00 PM CEST

• Predicting Treatment Effects of a New Drug in a Target Population Based on Randomized Controlled Trial Results

  Friday, August 26, 2022
  2:30 PM – 2:45 PM CEST

• Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

  Friday, August 26, 2022
  6:15 PM – 6:20 PM CEST

• Emulating Stratified Randomized Trials by Propensity Score Methods

  Saturday, August 27, 2022
  9:15 AM – 9:30 AM CEST

• Sodium-glucose Co-transporter 2 Inhibitors and the Risk of Early Bladder Cancer Events

  Saturday, August 27, 2022
  2:00 PM – 2:15 PM CEST

• Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-like peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

  Sunday, August 28, 2022
  9:30 AM – 9:45 AM CEST

• Emulation Differences versus Bias: Implications of Large-scale Emulation of Randomized Clinical Trials Using Clinical Practice Data (RCT-DUPLICATE)

  Sunday, August 28, 2022
  10:30 AM – 12:00 PM CEST

• Utilization Patterns of Systemic Immunomodulating Drugs in Patients with Atopic Dermatitis in Clinical Practice

  Sunday, August 28, 2022
  1:30 PM – 1:45 PM CEST